Overview
Also known as:
FDA & Trial Timeline
10 eventsM.D. Anderson Cancer Center — PHASE1
Institute of Hematology & Blood Diseases Hospital, China — EARLY_PHASE1
Beijing GoBroad Hospital — PHASE1, PHASE2
Shanghai Jiao Tong University School of Medicine — EARLY_PHASE1
Goethe University — PHASE2
First Affiliated Hospital of Zhejiang University — PHASE3
Iclusig: FDA approved
treatment of adult patients with newly diagnosed Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL) in combination with chemotherapy
The First Affiliated Hospital of Soochow University — EARLY_PHASE1
Assistance Publique - Hôpitaux de Paris
COPIKTRA: FDA approved
Treatment of adult patients with relapsed or refractory chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) after at least two prior therapies
Data sourced from FDA regulatory filings and ClinicalTrials.gov. Updated periodically.
Treatments
15 availableImatinib Mesylate
Adult patients with relapsed or refractory Philadelphia chromosome positive acute lymphoblastic leukemia (Ph+ ALL).
Blincyto
BLINCYTO is indicated for the treatment of CD19-positive B-cell precursor acute lymphoblastic leukemia (ALL) in first or second complete remission with minimal residual disease (MRD) greater than or e…
BLINCYTO is indicated for the treatment of CD19-positive B-cell precursor acute lymphoblastic leukemia (ALL) in first or second complete remission with minimal residual disease (MRD) greater than or equal to 0.1% in adult and pediatric patients one month and older.
Besponsa
BESPONSA is indicated for the treatment of relapsed or refractory CD22-positive B-cell precursor acute lymphoblastic leukemia (ALL) in adult and pediatric patients 1 year and older
Clolar
Clofarabine injection is indicated for the treatment of pediatric patients 1 to 21 years old with relapsed or refractory acute lymphoblastic leukemia after at least two prior regimens.
Arranon
indicated for the treatment of T-cell acute lymphoblastic leukemia (T-ALL) in adult and pediatric patients age 1 year and older whose disease has not responded to or has relapsed following treatment w…
indicated for the treatment of T-cell acute lymphoblastic leukemia (T-ALL) in adult and pediatric patients age 1 year and older whose disease has not responded to or has relapsed following treatment with at least 2 chemotherapy regimens
Imkeldi
Adult patients with relapsed or refractory Philadelphia chromosome positive acute lymphoblastic leukemia (Ph+ ALL).
Imatinib Mesylate
Adult patients with relapsed or refractory Philadelphia chromosome positive acute lymphoblastic leukemia (Ph+ ALL)
Aucatzyl
AUCATZYL is indicated for the treatment of adults with relapsed or refractory B-cell precursor acute lymphoblastic leukemia (ALL)
TECARTUS�
Adult patients with relapsed or refractory B-cell precursor acute lymphoblastic leukemia (ALL)
Marqibo
Treatment of adult patients with Philadelphia chromosome-negative (Ph-) acute lymphoblastic leukemia (ALL) in second or greater relapse or whose disease has progressed following two or more anti-leuke…
Treatment of adult patients with Philadelphia chromosome-negative (Ph-) acute lymphoblastic leukemia (ALL) in second or greater relapse or whose disease has progressed following two or more anti-leukemia therapies
Kymriah
KYMRIAH is indicated for treatment of patients up to 25 years of age with B-cell precursor acute lymphoblastic leukemia (ALL) that is refractory or in second or later relapse.
Iclusig
treatment of adult patients with newly diagnosed Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL) in combination with chemotherapy
COPIKTRA
Treatment of adult patients with relapsed or refractory chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) after at least two prior therapies
Kymriah (tisagenlecleucel)
Treatment of patients up to 25 years of age with B-cell precursor acute lymphoblastic leukemia (ALL) that is refractory or in second or later relapse
Vumon for injection
Induction therapy in patients with refractory childhood acute lymphoblastic leukemia when used in combination with other approved anticancer agents.
Rare Disease Specialist
Treatment Centers
8 centersBaylor College of Medicine Rare Disease Center ↗
Baylor College of Medicine
📍 Houston, TX
🏥 NORDStanford Medicine Rare Disease Center ↗
Stanford Medicine
📍 Stanford, CA
🔬 UDNNIH Clinical Center Undiagnosed Diseases Program ↗
National Institutes of Health
📍 Bethesda, MD
🔬 UDNUCLA UDN Clinical Site ↗
UCLA Health
📍 Los Angeles, CA
🔬 UDNBaylor College of Medicine UDN Clinical Site ↗
Baylor College of Medicine
📍 Houston, TX
🔬 UDNHarvard/MGH UDN Clinical Site ↗
Massachusetts General Hospital
📍 Boston, MA
🏥 NORDMayo Clinic Center for Individualized Medicine ↗
Mayo Clinic
📍 Rochester, MN
👤 Mayo Clinic Center for Individualized Medicine
🏥 NORDUCLA Rare Disease Day Program ↗
UCLA Health
📍 Los Angeles, CA
Financial Resources
7 resourcesTravel Grants
No travel grants are currently matched to Precursor T-cell acute lymphoblastic leukemia.
Community
No community posts yet. Be the first to share your experience with Precursor T-cell acute lymphoblastic leukemia.
Start the conversation →Latest news about Precursor T-cell acute lymphoblastic leukemia
1 articlesCaregiver Resources
NORD Caregiver Resources
Support, advocacy, and financial assistance for caregivers of rare disease patients.
Mental Health Support
Rare disease caregiving can be isolating. Connect with counseling and peer support.
Family & Caregiver Grants
Financial assistance programs specifically for caregivers of rare disease patients.
Social Security Disability
Learn how rare disease patients may qualify for SSDI/SSI benefits.
Common questions about Precursor T-cell acute lymphoblastic leukemia
Are there clinical trials for Precursor T-cell acute lymphoblastic leukemia?
Yes — 2 recruiting clinical trials are currently listed for Precursor T-cell acute lymphoblastic leukemia on UniteRare. See the clinical trials section on this page for phase, sponsor, and site details sourced from ClinicalTrials.gov.
Which specialists treat Precursor T-cell acute lymphoblastic leukemia?
17 specialists and care centers treating Precursor T-cell acute lymphoblastic leukemia are listed on UniteRare, sourced from ClinicalTrials.gov principal investigators, published research, and the NPPES NPI registry.
What treatment and support options exist for Precursor T-cell acute lymphoblastic leukemia?
8 patient support programs are currently tracked on UniteRare for Precursor T-cell acute lymphoblastic leukemia. See the treatments and support programs sections for copay assistance, eligibility, and contact details.